At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 5 enrolled
Drug / intervention
Xofigobiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BrUOG L301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases
In Brief
A Phase 2 clinical trial evaluating Xofigo for Non Small Cell Lung Cancer With Bone Metastatses. Completed, enrolled 5 participants across 1 site.
Detailed Summary
In this study patient's will receive the medicine Xofigo which is a radioactive drug that is FDA approved to treat prostate cancer that has spread to the bones. Xofigo has not previously been tested to treat lung cancer that has spread to the bones. Your doctors are studying the effects, good and bad, of Xofigo when used to treat lung cancer that has spread to the bones.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsRhode Island Hospital, The Miriam Hospital, Bayer
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartSep 2015
Primary CompletionJul 2018
Study CompletionNov 2018
TodayJul 2026
First PostedNov 5, 2014
Enrollment StartSep 1, 2015
Primary CompletionJul 5, 2018
Study CompletionNov 13, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.7 years ago
Interventions
Xofigobiological
This is a radio-isotope